Last reviewed 2026-04-20 · How we verify

Nerusil (BENMOXIN)

Phase 2 active Small molecule

Nerusil (generic name: BENMOXIN) is a benmoxin drug. It is currently in Phase 2 development.

Nerusil works by interacting with a specific biological target to produce its therapeutic effect.

Nerusil, also known as Benmoxin, is a small molecule drug in the benmoxin class. Its target and exact mechanism of action are unknown. It is not clear if Nerusil is FDA-approved or commercially available. Further information on its pharmacokinetics, safety, and efficacy is not available. As a result, its clinical use and commercial status remain unclear.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BENMOXIN
Drug class	benmoxin
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Nerusil is a key that fits into one of those locks. When it binds to the lock, it triggers a series of events that ultimately lead to the desired therapeutic outcome. However, the exact lock and mechanism by which Nerusil works are not well understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Nerusil CI brief — competitive landscape report
Nerusil updates RSS · CI watch RSS

Frequently asked questions about Nerusil

What is Nerusil?

Nerusil (BENMOXIN) is a benmoxin drug.

How does Nerusil work?

Nerusil works by interacting with a specific biological target to produce its therapeutic effect.

What is the generic name of Nerusil?

BENMOXIN is the generic (nonproprietary) name of Nerusil.

What drug class is Nerusil in?

Nerusil belongs to the benmoxin class. See all benmoxin drugs at /class/benmoxin.

What development phase is Nerusil in?

Nerusil is in Phase 2.

Drug class: All benmoxin drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing